Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 198.96 Billion KRW | -7.9% |
| 2022 | 216.02 Billion KRW | 5.69% |
| 2021 | 204.4 Billion KRW | 12.49% |
| 2020 | 181.7 Billion KRW | 1.64% |
| 2019 | 178.77 Billion KRW | 15.86% |
| 2018 | 154.29 Billion KRW | 13.3% |
| 2017 | 136.17 Billion KRW | 10.32% |
| 2016 | 123.43 Billion KRW | 47.27% |
| 2015 | 83.81 Billion KRW | -10.12% |
| 2014 | 93.25 Billion KRW | 53.72% |
| 2013 | 60.66 Billion KRW | 6.74% |
| 2012 | 56.83 Billion KRW | -0.08% |
| 2011 | 56.87 Billion KRW | -2.77% |
| 2010 | 58.49 Billion KRW | -0.69% |
| 2009 | 58.9 Billion KRW | 57.78% |
| 2008 | 37.33 Billion KRW | -20.01% |
| 2007 | 46.67 Billion KRW | -12.03% |
| 2006 | 53.05 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 44.59 Billion KRW | 6.0% |
| 2024 Q1 | 42.07 Billion KRW | -22.9% |
| 2023 Q4 | 54.57 Billion KRW | 3.52% |
| 2023 Q1 | 42.21 Billion KRW | -21.67% |
| 2023 Q3 | 52.71 Billion KRW | 4.72% |
| 2023 Q2 | 50.33 Billion KRW | 19.23% |
| 2023 FY | 198.96 Billion KRW | -7.9% |
| 2022 Q1 | 50.77 Billion KRW | -14.11% |
| 2022 FY | 216.02 Billion KRW | 5.69% |
| 2022 Q4 | 53.89 Billion KRW | -10.08% |
| 2022 Q3 | 59.94 Billion KRW | 16.6% |
| 2022 Q2 | 51.4 Billion KRW | 1.25% |
| 2021 Q2 | 46.05 Billion KRW | 1.09% |
| 2021 Q1 | 45.55 Billion KRW | -2.97% |
| 2021 FY | 204.4 Billion KRW | 12.49% |
| 2021 Q4 | 59.11 Billion KRW | 10.13% |
| 2021 Q3 | 53.68 Billion KRW | 16.57% |
| 2020 Q2 | 47.4 Billion KRW | 20.14% |
| 2020 Q4 | 46.94 Billion KRW | -2.01% |
| 2020 Q3 | 47.9 Billion KRW | 1.06% |
| 2020 Q1 | 39.45 Billion KRW | -9.64% |
| 2020 FY | 181.7 Billion KRW | 1.64% |
| 2019 Q1 | 43.87 Billion KRW | 18.89% |
| 2019 FY | 178.77 Billion KRW | 15.86% |
| 2019 Q4 | 43.66 Billion KRW | -2.69% |
| 2019 Q3 | 44.87 Billion KRW | -3.2% |
| 2019 Q2 | 46.35 Billion KRW | 5.67% |
| 2018 Q1 | 41.39 Billion KRW | 16.35% |
| 2018 FY | 154.29 Billion KRW | 13.3% |
| 2018 Q2 | 39.02 Billion KRW | -5.74% |
| 2018 Q3 | 36.97 Billion KRW | -5.25% |
| 2018 Q4 | 36.9 Billion KRW | -0.19% |
| 2017 Q3 | 35.38 Billion KRW | 6.6% |
| 2017 FY | 136.17 Billion KRW | 10.32% |
| 2017 Q1 | 32.02 Billion KRW | -3.62% |
| 2017 Q2 | 33.19 Billion KRW | 3.64% |
| 2017 Q4 | 35.58 Billion KRW | 0.57% |
| 2016 Q3 | 30.48 Billion KRW | 3.52% |
| 2016 Q4 | 33.22 Billion KRW | 9.01% |
| 2016 Q1 | 30.28 Billion KRW | 0.0% |
| 2016 Q2 | 29.44 Billion KRW | -2.76% |
| 2016 FY | 123.43 Billion KRW | 47.27% |
| 2015 Q3 | 25.69 Billion KRW | -7.24% |
| 2015 Q1 | 25.25 Billion KRW | 1.57% |
| 2015 FY | 83.81 Billion KRW | -10.12% |
| 2015 Q2 | 27.69 Billion KRW | 9.65% |
| 2014 Q2 | 20.11 Billion KRW | 36.7% |
| 2014 Q1 | 14.71 Billion KRW | -12.22% |
| 2014 FY | 93.25 Billion KRW | 53.72% |
| 2014 Q4 | 24.86 Billion KRW | 8.04% |
| 2014 Q3 | 23.01 Billion KRW | 14.45% |
| 2013 FY | 60.66 Billion KRW | 6.74% |
| 2013 Q1 | 13.98 Billion KRW | -6.21% |
| 2013 Q2 | 13.94 Billion KRW | -0.3% |
| 2013 Q3 | 15.24 Billion KRW | 9.35% |
| 2013 Q4 | 16.76 Billion KRW | 9.92% |
| 2012 Q1 | 13.51 Billion KRW | -5.5% |
| 2012 Q2 | 14.21 Billion KRW | 5.13% |
| 2012 Q3 | 13.57 Billion KRW | -4.48% |
| 2012 FY | 56.83 Billion KRW | -0.08% |
| 2012 Q4 | 14.91 Billion KRW | 9.84% |
| 2011 Q2 | 14.28 Billion KRW | 1.83% |
| 2011 Q1 | 14.02 Billion KRW | -2.32% |
| 2011 FY | 56.87 Billion KRW | -2.77% |
| 2011 Q4 | 14.3 Billion KRW | -3.15% |
| 2011 Q3 | 14.77 Billion KRW | 3.42% |
| 2010 Q3 | 14.67 Billion KRW | -5.02% |
| 2010 Q1 | - KRW | -100.0% |
| 2010 FY | 58.49 Billion KRW | -0.69% |
| 2010 Q2 | 15.44 Billion KRW | 0.0% |
| 2010 Q4 | 14.35 Billion KRW | -2.13% |
| 2009 Q1 | 5.55 Billion KRW | -53.64% |
| 2009 FY | 58.9 Billion KRW | 57.78% |
| 2009 Q4 | 12.06 Billion KRW | 1.77% |
| 2009 Q3 | 11.85 Billion KRW | -11.3% |
| 2009 Q2 | 13.36 Billion KRW | 140.53% |
| 2008 Q4 | 11.98 Billion KRW | 5.0% |
| 2008 FY | 37.33 Billion KRW | -20.01% |
| 2008 Q3 | 11.41 Billion KRW | 36.18% |
| 2008 Q2 | 8.38 Billion KRW | 14.38% |
| 2008 Q1 | 7.32 Billion KRW | -42.65% |
| 2007 Q2 | 13.66 Billion KRW | 0.0% |
| 2007 Q4 | 12.77 Billion KRW | -0.97% |
| 2007 FY | 46.67 Billion KRW | -12.03% |
| 2007 Q3 | 12.9 Billion KRW | -5.61% |
| 2006 FY | 53.05 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -327.828% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 45.356% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -0.038% |
| HANDOK Inc. | 151.36 Billion KRW | -31.444% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -195.966% |
| Yuhan Corporation | 564.5 Billion KRW | 64.755% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 38.251% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -737.837% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 76.197% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -165.143% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -389.456% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -110.507% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -41.252% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -327.828% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -473.116% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -159.003% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 1751.737% |
| JW Holdings Corporation | 446.15 Billion KRW | 55.405% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 4.133% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 69.64% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 40.727% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -153.068% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -164.443% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -175.526% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -8.241% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -327.828% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 32.582% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 70.807% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 40.727% |
| Yuhan Corporation | 564.5 Billion KRW | 64.755% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 1.417% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -180.468% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -100.917% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 40.727% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -36.377% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -14.683% |
| CKD Bio Corp. | 5.01 Billion KRW | -3871.053% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 21.74% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -8.058% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -102.763% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -153.068% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 46.443% |
| Boryung Corporation | 333.26 Billion KRW | 40.3% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -297.562% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 0.0% |
| JW Lifescience Corporation | 51.32 Billion KRW | -287.651% |